Last C$2.44 CAD
Change Today -0.025 / -1.02%
Volume 759.1K
PLI On Other Exchanges
Symbol
Exchange
OTC US
Toronto
Frankfurt
As of 10:27 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

prometic life sciences inc (PLI) Snapshot

Open
C$2.46
Previous Close
C$2.46
Day High
C$2.47
Day Low
C$2.43
52 Week High
02/23/15 - C$2.50
52 Week Low
04/29/14 - C$0.85
Market Cap
1.3B
Average Volume 10 Days
3.9M
EPS TTM
C$-0.03
Shares Outstanding
551.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROMETIC LIFE SCIENCES INC (PLI)

Related News

No related news articles were found.

prometic life sciences inc (PLI) Related Businessweek News

No Related Businessweek News Found

prometic life sciences inc (PLI) Details

ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparation, plasma-derived therapeutics, and small-molecule drugs. The company also offers its technologies for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutics products targeting unmet medical needs in the fields of fibrosis, anemia, cancer, and autoimmune disease, as well as plasma-derived therapeutics in orphan drug indications. It operates in two segments, Therapeutics and Protein Technology. The Therapeutics segment’s lead product includes PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. This segment also develops PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases; and PBI-1402, a drug candidate for the treatment of anemia indications. The Protein Technology segment provides plasma protein purification system, a solution for the extraction and purification of therapeutic proteins from human plasma; bioseparation products based on applications of its patented Mimetic Ligand technology for various biopharmaceutical companies; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

Founded in 1992

prometic life sciences inc (PLI) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: C$435.0K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: C$322.3K
Chief Executive Officer of ProMetic BioScienc...
Total Annual Compensation: C$238.5K
General Counsel and Corporate Secretary
Total Annual Compensation: C$197.0K
Senior Vice President of Product & Asia Pacif...
Total Annual Compensation: C$283.6K
Compensation as of Fiscal Year 2013.

prometic life sciences inc (PLI) Key Developments

US FDA Grants Orphan Drug Designation to ProMetic's PBI-4050 Drug for the Treatment of Idiopathic Pulmonary Fibrosis

ProMetic Life Sciences Inc. announced that an orphan drug designation status has been granted for its orally active anti-fibrotic lead drug candidate, PBI-4050, for the treatment of idiopathic pulmonary fibrosis. In gold standard animal models proven to emulate pulmonary fibrosis in humans, PBI-4050 performed favorably compared to recently approved drugs to treat such condition. PBI-4050 significantly reduced tissue scarring in the lungs observed in non-treated animals, indicating the potential for clinically significant improvement and stabilization in lung function. Moreover, the combination of PBI-4050 and another approved drug generated unprecedented reduction of fibrotic markers in this model, suggesting that synergistic clinical benefit may be found. Health Canada has recently cleared PBI-4050 to commence clinical trials in patients suffering from IPF. Orphan Drug Designation is granted to drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven year period of U.S. marketing exclusivity upon marketing approval for the designated indication, as well as with tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and the waiver of prescription drug user fees. ProMetic has successfully completed its PBI-4050 Phase I clinical trial in 40 healthy volunteers, in which it was found to be safe and well tolerated, with no serious adverse events. The Corporation has also completed the enrolment of patients with diabetic kidney disease (DKD) in the multi-dose part of the currently ongoing Phase Ib trial and is expected to report results thereon by the end of the first quarter of 2015. Health Canada has also cleared PBI-4050 to commence clinical trials in patients suffering from the metabolic syndrome and resulting Type 2 diabetes.

ProMetic Life Sciences Inc. Receives $11.4 Million Purchase Order from Multinational Client

ProMetic Life Sciences Inc. announced that it has received an $11.4 million purchase order for the supply of affinity resin from an existing client. The affinity resin will be manufactured by ProMetic at its Isle of Man facility and supplied to the client throughout the second half of 2015 and the first half of 2016. ProMetic's client will use the resin for purification of a therapeutic protein product manufactured.

ProMetic Life Sciences Inc. Announces Clearance of PBI-4050, its Orally Active Anti-Fibrotic Lead Drug Candidate, to Commence Clinical Trials in Patients with Idiopathic Pulmonary Fibrosis

ProMetic Life Sciences Inc. reported that its orally active anti-fibrotic lead drug candidate, PBI-4050, has been approved to commence the clinical trial in patients suffering from idiopathic pulmonary fibrosis, following the CTA clearance by Health Canada. In a gold standard animal model proven to emulate pulmonary fibrosis in humans, PBI-4050 performed favorably compared to recently approved drugs to treat such condition. PBI-4050 significantly reduced tissue scarring in the lungs otherwise observed in non-treated animals. Moreover, the combination of PBI-4050 and Pirfenidone generated unprecedented reduction of fibrotic markers, indicating the potential for clinically significant improvement and stabilization in lung function. The objectives of this 12 weeks open-label, single-arm, exploratory Phase II study are to evaluate the safety and tolerability of PBI-4050 in 40 patients suffering from IPF and to gather data on the effects of PBI-4050 on pulmonary function, disease progression and inflammatory/fibrotic markers. ProMetic has successfully completed its PBI-4050 Phase I clinical trial in 40 healthy volunteers, in which it was found to be safe and well tolerated, with no serious adverse events. The Corporation has also started enrolling patients with diabetic kidney disease (DKD) in the multi-dose part of the Phase Ib trial and is expected to report results thereon by the end of the first quarter of 2015. Idiopathic pulmonary fibrosis (IPF) is a chronic, devastating, and ultimately fatal disease characterized by a progressive decline in lung function. It is a specific type of interstitial lung disease in which the small air sacs of the lung, the "alveoli," gradually become replaced by fibrotic (scar) tissue and is the cause of worsening dyspnea (shortness of breath). IPF is usually associated with a poor prognosis. The term 'idiopathic' is used because the cause of pulmonary fibrosis is still unknown. IPF usually occurs in adult individuals of between 50 and 70 years of age, particularly those with a history of cigarette smoking, and affects men more often than women. IPF affects about 130,000 people in the United States, with about 48,000 new cases diagnosed annually. Approximately 40,000 people die each year with IPF, a similar number of deaths to those due to breast cancer. The 5-year mortality rate for patients with IPF is estimated to range from 50% to 70%. PBI-4050 is an orally active lead drug candidate with excellent safety and efficacy profiles confirmed in several in vivo experiments targeting fibrosis. Fibrosis is a very complex process by which continuing inflammation causes vital organs to lose their function as normal tissue is replaced by fibrotic scar tissue. The proof of concept data generated to date confirms the lead drug candidates' anti-fibrotic activity in several key organs including the kidneys, the heart, the lungs and the liver. Twenty six million patients in the U.S. alone are diagnosed with chronic kidney diseases (CKD). Patients with severe CKD stages (3 and 4) suffer from a gradual and accelerated loss of their renal function (end-stage renal disease or ESRD) leading to the need for hemodialysis. Cardiovascular complications for ESRD patients on hemodialysis are a common cause of death.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLI:CN C$2.44 CAD -0.025

PLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PLI.
View Industry Companies
 

Industry Analysis

PLI

Industry Average

Valuation PLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 66.6x
Price/Book 39.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 66.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROMETIC LIFE SCIENCES INC, please visit www.prometic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.